Revolution Medicines, Inc. Accrued Royalties (Current) increased by 4.5% to $280.64M in Q1 2026 compared to the prior quarter.
An increase typically signals successful progress toward milestones or increased licensing activity, while a decrease indicates payments have been settled.
This represents the liability for royalty payments that have been earned by licensors based on research or development m...
Common in biotech and pharma companies that license intellectual property from academic institutions or other firms.
accrued_royalties_current| Q4 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $0.00 | $245.08M | $256.51M | $268.45M | $280.64M |
| QoQ Change | — | — | +4.7% | +4.7% | +4.5% |